BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024
Language flag

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

Biostock PHI one year CEO anniversary

BioStock: PHI “We aim to revolutionize the regenerative medicine market“

BioStock talked to PHI’s CEO, Patrik Eschricht, about the eventful past year and his vision for the company’s future within regenerative medicine.
BioStock-PHI-CEO-reflects-on-the-company-momentum

BioStock: PHI’s CEO reflects on the Company’s momentum

BioStock reached out to PHI’s CEO, Patrik Eschricht, to delve into what latest developments have contributed to the heightened enthusiasm surrounding the company.
Biostock-Altium-fuels-PHIs-forward-drive

BioStock: Altium fuels PHI’s forward drive

BioStock connects with Goran Dubravčić, Altium’s CEO and PHI’s newly appointed Chairman of the Board, to explore the current pivotal developments and their impact on PHI’s trajectory.
Businesspeople brainstorming together with sticky notes in an of

BioStock: PHI links up with two regenerative medicine networks

BioStock contacted CEO Patrik Eschricht to learn more about the company’s future strategies in regenerative medicine and the pivot toward the clinical market.
1…34567…10

Latest News

Altium SA places order to a value of EUR 460 K and PHI communicates sales outlook

PHI AB today announces that the Company’s global distributor Altium SA has placed an order of HoloMonitor® systems and add-ons to a total value of approximately EUR 460 K. The total expected order value from Altium for the full fiscal year of 2024/2025 is estimated to amount to approximately EUR 2 million.
HoloMonitor-holography-red-light

Interim Report 2 2024/25

Sales grew significantly in Q2 vs. the same period last year, but only moderately YTD vs. the same period last year. Discounting on demo kits for our new distributors reduced the gross margin. Overall costs remain stable. The absolute key to transforming the company, both short-term and long-term, is a significant increase in sales, which the agreement with Altium promises to deliver.

Early publication of Interim Report 2, 2024/2025

Phase Holographic Imaging PHI AB (publ) hereby announces that the Board of Directors has decided to bring forward the company’s report for Q2, 2024/2025 to November 28, 2024. This is because the company wishes to publish the report prior to the Extraordinary General Meeting planned for Dec 2.
See All News